Announcement
23 Apr 2026
In April 2026, the United States government announced an agreement with Regeneron to implement most-favoured-nation drug pricing for American patients.
Source
Sign in to access
Number of interventions
3
0 certainly harmful
3 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 24 Apr 2026
Local operations incentive
Recent update from 24 Apr 2026:
On 23 April 2026, the United States announced an agreement with Regeneron. According to Regeneron's press release, under the agreement, Regeneron will be free from Section 232 tariffs on its import...
Sign in to see more
Updated: 24 Apr 2026
Tax or social insurance relief
Recent update from 24 Apr 2026:
On 23 April 2026, the United States announced reaching an agreement with Regeneron. According to Regeneron's press release, the company will be free from Section 232 tariffs on its imported product...
Sign in to see more
Updated: 24 Apr 2026
Import tariff
Recent update from 24 Apr 2026:
On 23 April 2026, the United States announced an agreement with Regeneron under which the company agreed to implement most-favoured-nation pricing for its drugs and to make investments in U.S. manu...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.